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Summary
Background Bidis are minimally regulated, inexpensive, hand-rolled tobacco products smoked in south Asia. We 
examined the eﬀ ects of bidi smoking on baseline respiratory impairment, and prospectively collected data for all-cause 
mortality and cardiorespiratory events in men from this region.
Methods This substudy of the international, community-based Prospective Urban Rural Epidemiology (PURE) study 
was done in seven centres in India, Pakistan, and Bangladesh. Men aged 35–70 years completed spirometry testing 
and standardised questionnaires at baseline and were followed up yearly. We used multilevel regression to compare 
cross-sectional baseline cardiorespiratory symptoms, spirometry measurements, and follow-up events (all-cause 
mortality, cardiovascular events, respiratory events) adjusted for socioeconomic status and baseline risk factors 
between non-smokers, light smokers of bidis or cigarettes (≤10 pack-years), heavy smokers of cigarettes only (>10 pack-
years), and heavy smokers of bidis (>10 pack-years).
Findings 14 919 men from 158 communities were included in this substudy (8438 non-smokers, 3321 light smokers, 
959 heavy cigarette smokers, and 2201 heavy bidi smokers). Mean duration of follow-up was 5·6 years (range 1–13). 
The adjusted prevalence of self-reported chronic wheeze, cough or sputum, dyspnoea, and chest pain at baseline 
increased across the categories of non-smokers, light smokers, heavy cigarette smokers, and heavy bidi smokers 
(p<0·0001 for association). Adjusted cross-sectional age-related changes in forced expiratory volume in 1 s (FEV1) 
and FEV1/forced vital capacity (FVC) ratio were larger for heavy bidi smokers than for the other smoking categories. 
Hazard ratios (relative to non-smokers) showed increasing hazards for all-cause mortality (light smokers  1·28 
[95% CI 1·02–1·62], heavy cigarette smokers 1·59 [1·13–2·24], heavy bidi smokers 1·56 [1·22–1·98]), cardiovascular 
events (1·45 [1·13–1·84], 1·47 [1·05–2·06], 1·55 [1·17–2·06], respectively) and respiratory events (1·30 [0·91–1·85], 
1·21 [0·70–2·07], 1·73 [1·23–2·45], respectively) across the smoking categories.
Interpretation Bidi smoking is associated with severe baseline respiratory impairment, all-cause mortality, and 
cardiorespiratory outcomes. Stricter controls and regulation of bidis are needed to reduce the tobacco-related disease 
burden in south Asia.
Funding Population Health Research Institute, Canadian Institutes of Health Research, and Heart and Stroke 
Foundation of Ontario.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
Tobacco use is the world’s leading preventable cause of 
premature death.1 The harmful eﬀ ects of cigarette 
smoking have been extensively studied and are 
universally accepted. Less is known about the health 
eﬀ ects of non-cigarette tobacco products, such as bidis 
(also known as beedis), which are commonly used in 
populations of low socioeconomic status.
Bidis are inexpensive, small, hand-rolled tobacco 
products commonly smoked in south Asia. Estimates 
suggest that there were 53 million users of bidis in India 
and Bangladesh in 2003–09.2 Outside this region, bidi use 
has mainly been reported in young adults in developed 
countries,3 where unregulated marketing over the 
internet and in ethnic stores has allowed easy access to 
this vulnerable population. Bidis are manufactured in 
south Asia by a cottage industry that has avoided many of 
the local and international tobacco regulations and taxes 
enforced on factory-made cigarettes. Consequently, bidis 
are sold cheaply, at various prices and in packaging with 
poorly visible health warnings.4–6 Furthermore, herbal and 
ﬂ avoured varieties are made to appeal to young adults as 
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“natural and safe” tobacco alternatives to cigarettes.3 This 
claim contrasts with the toxicology data, which have 
shown higher nicotine, tar, and carbon monoxide levels 
delivered for a lower content of tobacco in bidis than in 
cigarettes.7 However, there is a paucity of clinical data on 
the health eﬀ ects of bidis. Most of these data are derived 
from retrospective, cross-sectional, or case-control 
studies, most with small sample sizes and limited 
adjustments for a wide range of potential confounders.8–11
We prospectively assessed the eﬀ ects of bidi and 
cigarette smoking on mortality, respiratory, and 
cardiovascular outcomes in an unselected community-
based cohort of men in south Asia. All comparisons 
were adjusted for diﬀ erences in socioeconomic status, 
user-speciﬁ c characteristics, and baseline risk factors. 
Furthermore, cross-sectional comparisons of self-
reported baseline respiratory symptoms and spirometry 
measurements were done to provide information about 
baseline respiratory morbidity. The high prevalence of 
low-intensity smoking (ie, ≤10 pack-years) in this cohort 
provided an opportunity to assess the eﬀ ects of low-
intensity tobacco smoking on health outcomes.
Methods
Study design and participants
This substudy of the Prospective Urban Rural 
Epidemiology (PURE) study included community-based 
participants from India (ﬁ ve centres), Pakistan (one 
centre), and Bangladesh (one centre). Details of the 
overall PURE study design have been described 
elsewhere12 and are summarised in the appendix (pp 5–9).
The centres were purposely chosen to provide a diverse 
range of economic, physical, and sociocultural 
environments, balanced by the feasibility of centres to 
achieve long-term follow-up. Standardised approaches 
were used for the enumeration of households, 
identiﬁ cation of individuals, recruitment, and data 
collection. The methods of approaching households 
diﬀ ered between countries, but aimed to avoid biases in 
participant selection. Households with at least one 
member aged 35–70 years who were intending to stay 
locally for more than 4 years were approached. The ﬁ nal 
sample size for analysis varied by the outcome of interest 
and included only men with no missing data relevant for 
the outcome of interest. Only men were selected because 
the rate of smoking in women in south Asia were low. 
Similarly, former and current smokers were combined as 
ever-smokers for all analyses.
 All eligible individuals who provided written informed 
consent were enrolled. Baseline data were collected from 
Jan 1, 2003, to Dec 30, 2009, and follow-up data from 
Jan 1, 2008, to Dec 30, 2013. The study was coordinated 
by the Population Health Research Institute (Hamilton, 
ON, Canada) and approved by the Hamilton Health 
Sciences Research Ethics Board and by the local ethics 
committee at each site.
Procedures
Standardised interview-based questionnaires adapted 
from previous cohort studies (appendix p 10) were 
administered by trained personnel to household 
members  aged 35–70 years. The questionnaire elicited 
demographic, household, behavioural, and medical 
information (risk factors, symptoms, comorbid 
disorders). Bidi and cigarette use was deﬁ ned as self-
reported duration of use more than 0 days or quantity 
Research in context
Evidence before this study
We searched PubMed, Embase, the Cochrane database, and 
bibliographies of retrieved articles for relevant reports published 
in English between Jan 1, 1960, and Jan 1, 2016. We used 
key search terms “beedi”, “beedis”, “bidi”, “bidis”, 
“tobacco-smoking”, and “India”, “south Asia” to identify reports 
of bidi smoking on health outcomes including mortality, 
cardiorespiratory health, and lung function in south Asia. We 
found few reports published after 2000. Previous publications 
were not methodologically robust, and reported data derived 
from retrospective, cross-sectional, or case-control studies with 
limited and variable adjustments for potential confounders such 
as diﬀ erences in socioeconomic and baseline risk factors. 
Furthermore, very few studies directly compared the eﬀ ects of 
bidi smoking with cigarette smoking on cardiorespiratory 
outcomes and lung function.
Added value of this study
To our knowledge, this is the largest prospective multisite 
study with standardised approaches for data collection 
(covariates, cardiorespiratory symptoms, and lung function 
measurements) and ascertainment of follow-up outcomes 
(deaths and cardiorespiratory events) in India, Bangladesh, 
and Pakistan. We examined the eﬀ ects of cigarette and bidi 
smoking on several outcomes, adjusting for important 
diﬀ erences in socioeconomic and baseline risk factors. A 
coherent pattern of worst outcomes was seen for bidi 
smokers, including highest self-reported baseline respiratory 
symptoms, obstructive ventilatory impairment, and 
follow-up mortality and cardiorespiratory events compared 
with cigarette smokers and non-smokers.
Implications of all the available evidence
Our ﬁ ndings ﬁ ll an important gap in knowledge about the 
many harmful health eﬀ ects of bidi smoking. These ﬁ ndings 
can be used for evidence-based practice and policy making 
that will help bring about greater controls on bidi use in 
south Asia. 
See Online for appendix
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more than none per day. Former smokers were deﬁ ned 
as individuals who had not smoked for at least 
12 months. Participants were classiﬁ ed into four 
categories based on the number of pack-years of 
smoking (duration [years] × quantity [sticks per day] 
divided by 20) and tobacco type: non-smokers of bidis 
or cigarettes (never-smokers), light smokers of either or 
both products (≤10 pack-years), heavy smokers of 
cigarettes only (>10 pack-years), and heavy smokers of 
bidis (including concurrent use of cigarettes; >10 pack-
years). Other relevant data included cooking fuel (solid 
or kerosene vs gas or electricity), education, asset index, 
proportion of income spent on food, physical activity, 
dietary intake, and cardio respiratory symptoms 
(dyspnoea with usual activity; wheeze; cough or 
sputum; chest pain) occurring at least weekly in the 
previous 6 months.
Household owned items were used to generate an asset 
index, an indicator of wealth. Physical activity was 
assessed with the International Physical Activity 
Questionnaire (IPAQ).13 Dietary intake was assessed with 
a validated food frequency questionnaire.14 Physical 
measurements were collected by standardised methods 
for anthropometrics, blood pressure, handgrip strength, 
and spirometry. An individualised INTERHEART risk 
score was calculated with the version excluding 
cholesterol concentration. This score provided a validated 
and quantitative measure of the risk-factor burden for 
cardiovascular disease, which incorporates information 
about self-reported age, sex, cigarette use, diabetes, 
family history of cardiovascular disease, psychosocial 
factors, diet, physical activity, and measured waist-to-hip 
ratio and hypertension (≥140/90 mm Hg).15
Lung function was measured with a portable spirometer 
(MicroGP, MicroMedical Ltd, Chatham, IL,  USA), which 
did not generate spirograms. Each participant attempted 
up to six forced prebronchodilator manoeuvres while 
standing and wearing a nose clip. Each manoeuvre was 
closely observed for maximal eﬀ ort, with exhalation time 
6 s or more and without coughing. Spirometers were 
calibrated monthly (3 L syringe) or before each use in 
extreme temperature or handling. For analyses, we 
selected participants with at least two forced expiratory 
volume in 1 s (FEV1) and forced vital capacity (FVC) 
measurements within 200 mL variability. The quality of 
the spirometry data in PURE have previously been 
Figure 1: Participant selection for the substudy
PURE=Prospective Urban Rural Epidemiology Study. *Participants with poor-quality lung function data were those with less than two measurements of forced 
expiratory volume in 1 s (FEV1) or forced vital capacity (FVC), or with variability between two the highest FEV1 or FVC measurements of >200 mL. †Participants with 
self-reported diagnoses of cardiorespiratory disease, stroke, cancer, tuberculosis, or HIV infection at baseline were excluded from the analysis of follow-up events. 
160 405 participants enrolled in PURE study
126 523 from outside south Asia excluded
33 882 from south Asia
18 915 women excluded because of low smoking rate
14 967 men
14 919 included in substudy
 8438 non-smokers
 6481 smokers
 3321 ≤10 pack-years of smoking
 3160 >10 pack-years of smoking
12 041 included in analysis of baseline lung 
 function
14 919 included in analysis of baseline 
 cardiorespiratory symptoms
13 264 included in analysis of follow-up events 
 (all-cause mortality, cardiovascular 
 events, respiratory events)
48 excluded because of missing data for smoking
2878 excluded because of absent or 
 poor-quality lung function data*
1655 excluded
 217 missing follow-up data
 1438 presence of self-reported 
  chronic diseases at baseline†
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validated for external, internal, and face validity (appendix 
pp 11–16).16 The highest FEV1, FVC, and FEV1/FVC ratio 
recorded for each individual was included in the analysis.
Participants were followed up with yearly telephone 
calls and face-to-face interviews every 3 years. At each 
contact, participants, or close relatives in cases of deaths 
(via verbal autopsy17), were questioned as to whether any 
clinical events had occurred and if so, documentation 
was obtained for event adjudication by the site 
investigators using standard deﬁ nitions (appendix 
pp 17–20). Furthermore, a random subset of events from 
each site was assessed centrally (Population Health 
Research Institute) to ensure consistency in the 
adjudicated events.
To ensure standardisation and data quality, comp-
rehensive operations manuals, reinforced by periodic 
training workshops, training DVDs, and regular 
communication were used in all sites. Data were entered 
locally by each site into a customised database programmed 
with range and consistency checks and transmitted 
electronically to the coordinating centre, where further 
quality control measures were implemented.
Statistical analysis
We used multilevel marginal regression to estimate the 
eﬀ ect size by smoking category on outcomes relative to 
non-smokers adjusted for age, body-mass index, asset 
index, education, cooking fuel, INTERHEART risk score, 
diabetes, hypertension, and centre (except for spirometry 
measurements and respiratory events). Community was 
treated as a random eﬀ ect to account for data clustering. 
Logistic regression provided estimates on the adjusted 
prevalence and odds ratios (ORs) for cross-sectional 
baseline symptoms. We used linear regression to compare 
the cross-sectional age-related changes on baseline FEV1 
and FEV1/FVC ratio by smoking category adjusted for 
height, weight, centre, and education (FEV1) or age, height, 
and centre (FEV1/FVC ratio). We used Cox proportional 
hazards models to estimate the incidences and hazard 
ratios (HRs) for all-cause mortality and cardiovascular 
events (myocardial infarction, stroke, heart failure, sudden 
death, cardiovascular-related death, and cardiovascular-
related hospital admission). For respiratory events (chronic 
obstructive pulmonary disease, asthma, pneumonia, 
tuberculosis), the same Cox model was used but without 
INTERHEART risk score, diabetes, and hypertension as 
covariates. To compare the eﬀ ect size estimates by smoking 
category, smoking category was ﬁ tted as a categorical 
variable and its coeﬃ  cient reﬂ ects the nature of association 
between eﬀ ect size and smoking category.
There was no formal sample size calculation for this 
substudy. We assessed the adequacy of the sample size 
using guidelines proposed by Concato and colleagues,18 
which recommend that for Cox regression at least 
ten events for each degree of freedom (df) are needed to 
provide stable models. There were 685 deaths, 
552 cardiovascular events, and 269 respiratory events 
recorded during follow-up. The model for deaths and 
cardiovascular events contained nine covariates including 
the smoking categories, giving a total of 22 df. For the 
respiratory event model, there were ﬁ ve covariates giving 
a total of 16 df. Thus the events per df for mortality, 
cardiovascular, and respiratory events were 31 (685/22), 
25 (552/22), and 16 (269/16), respectively. These estimates 
are all greater than ten events per df, indicating the 
sample size was adequate to provide stable models for all 
three event outcomes. 
Some sensitivity analyses were carried out to examine 
for any changes to our main ﬁ ndings on outcome events 
using diﬀ erent criteria for selection of study population 
(including participants with signiﬁ cant baseline 
comorbidities); classiﬁ cation of smoking categories 
(excluding former smokers or smokers of both bidis and 
cigarettes) and using diﬀ erent socioeconomic status 
covariates (education, rural or urban location, percent 
income spent of food, and the combination of these). All 
Non-smokers 
(n=8438)
Light smokers 
(n=3321)
Heavy cigarette 
smokers 
(n=959)
Heavy bidi 
smokers 
(n=2201)
Tobacco type
Cigarettes only ·· 1811 (55%) 959 (100%) 0
Bidis only ·· 1330 (40%) 0 1627 (74%)
Both ·· 180 (5%) 0 574 (26%)
Smokeless tobacco use* 696 (8%) 227 (7%) 57 (6%) 121 (5%)
Age (years) 49·3  (10·6) 47·9 (10·0) 53·0 (9·1) 51·9 (10·1)
Height (cm) 164·9 (7·4) 165·1 (7·2) 165·4 (6·9) 164·2 (6·7)
Weight (kg) 63·6 (13·7) 59·8 (13·4) 63·2 (13·6) 54·0 (10·8)
Body-mass index (kg/m²) 23·4 (4·4) 22·0 (4·3) 23·0 (3·9) 20·2 (3·5)
Urban residency 4649 (55%) 1414 (43%) 578 (60%) 504 (23%)
Education
Secondary or higher 5595 (67%) 1836 (56%) 633 (66%) 615 (28%)
Primary or none 2695 (33%) 1456 (44%) 321 (34%) 1573 (72%)
Missing data 148 (2%) 29 (1%) 5 (1%) 13 (1%)
Asset index† –0·8 (1·0) –1·3 (0·8) –0·7 (0·7) –1·5 (0·5)
Proportion of income spent 
on food (%)‡
54·3% (26·2) 62·3% (25·0) 58·5% (23·1) 68·3% (22·4)
Cooking fuel
Gas or electricity 4735 (61%) 1338 (43%) 583 (62%) 394 (21%)
Kerosene or solid fuel 3021 (39%) 1751 (57%) 353 (38%) 1502 (79%)
Missing data 682 (8%) 232 (7%) 23 (2%) 305 (14%)
Manual labour occupations§ 2267/8438 
(45%)
987/3321 (63%) 421/959 (60%) 1114/ (87%)
Location¶
Bangladesh 572 (7%) 312 (9%) 211 (22%) 238 (11%)
Chandigarh, India 1392 (16%) 89 (3%) 18 (2%) 127 (6%)
Chennai, India 1265 (15%) 473 (14%) 116 (12%) 306 (14%)
Thiruvananthapuram, 
India
985 (12%) 549 (17%) 309 (32%) 228 (10%)
Bengaluru, India 2487 (29%) 1426 (43%) 146 (15%) 792 (36%)
Jaipur, India 1190 (14%) 344 (10%) 13 (1%) 507 (23%)
Pakistan 547 (6%) 128 (4%) 146 (15%) 3 (<1%)
(Table 1 continues on next page)
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analyses were done with SAS version 9.2. No adjustments 
for multiplicity of analysis were made.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication. 
Results
14 919 men from 158 communities across seven centres in 
south Asia were included in this substudy (ﬁ gure 1). Bidi 
smoking was more common in India, whereas cigarette 
smoking was more common in Bangladesh and Pakistan 
(table 1). A small proportion of smokers reported using 
both tobacco types; bidis were the predominant type. The 
demographics of participants who smoked both bidis and 
cigarettes were similar to the demographics of those who 
smoked bidis only; we therefore reclassiﬁ ed this group as 
bidi smokers (appendix p 21). A small and similar 
proportion of participants across the smoking categories 
reported the use of smokeless tobacco. There was a small 
proportion of former smokers and the numbers were 
evenly distributed across the smoking categories. Overall, 
heavy bidi smokers were more likely to come from rural 
communities and have a low socioeconomic status than 
were men in all other smoking categories (lower 
education and asset index; higher percentages of income 
spent on food, manual labour occupations, and use of 
solid or kerosene cooking fuels).
The adjusted prevalence of self-reported chronic 
cardiorespiratory symptoms at baseline was signiﬁ cantly 
higher in heavy cigarette smokers and heavy bidi smokers 
than in non-smokers (table 2, ﬁ gure 2). The largest eﬀ ect 
was seen for chronic cough and sputum. Light smokers 
showed a modest increase in adjusted prevalence of 
chronic symptoms relative to non-smokers; however, 
because of low reported rates of wheeze and dyspnoea, 
the increase in these symptoms was not signiﬁ cant. The 
prevalence of chronic symptoms at baseline increased 
across the categories of non-smokers, light smokers, 
heavy cigarette smokers, and heavy bidi smokers 
(p<0·001 for association).
For the cross-sectional analysis of spirometry measure-
ments, centres from Pakistan, Jaipur (India), and 
Bangladesh were excluded because of high proportions of 
participants with missing spirometry data (ﬁ gure 1). We 
therefore examined spirometry data from the ﬁ ve centres 
in India. The adjusted cross-sectional age-related changes 
in FEV1 and FEV1/FVC ratio were signiﬁ cantly larger for 
heavy bidi smokers than for men in the other smoking 
categories (table 3, ﬁ gure 3). This ﬁ nding suggests 
increasingly lower lung function in the older age groups of 
bidi smokers. By contrast, age-related changes in FEV1 did 
not diﬀ er between non-smokers, light smokers, and heavy 
cigarette smokers. However, similar pairwise comparison 
showed a signiﬁ cantly reduced FEV1/FVC ratio, suggesting 
mild obstructive ventilatory impairment, in light smokers 
and heavy cigarette smokers compared with non-smokers.
Mean duration of follow-up was 5·6 years (range 1–13). 
13 264 (98%) participants completed follow-up, with a 
similar proportion in each smoking category (7554 [98%] 
non-smokers; 2966 [98%] light smokers; 819 [99%]  heavy 
cigarette smokers; 1925 [98%]  heavy bidi smokers). 
Participants with self-reported baseline cardiovascular 
disease, respiratory disease, cancer, or HIV infection 
were excluded from the analysis of follow-up events 
(ﬁ gure 1). The demographics of the excluded and 
included participants were similar (appendix pp 21). In 
the analysis population, there were 685 deaths, 
552 cardiovascular events, and 269 respiratory events 
(table 4). Heavy bidi smokers had the highest incidence 
of follow-up events compared with men in the other 
smoking categories (table 4, ﬁ gure 4). The largest eﬀ ect 
of heavy bidi smoking was on respiratory events. The 
incidence of follow-up events in light smokers and heavy 
cigarette smokers was intermediate between that for 
non-smokers and heavy bidi smokers; however, the 
increase in incidence of respiratory events in light 
smokers and heavy cigarette smokers compared with 
non-smokers was not signiﬁ cant. The HRs for follow-up 
events increased across the categories of light smokers, 
heavy cigarette smokers, and heavy bidi smokers.
We did sensitivity analyses that included all participants 
with complete vital statistics; adjusted for other indicators 
Non-smokers 
(n=8438)
Light smokers 
(n=3321)
Heavy cigarette 
smokers 
(n=959)
Heavy bidi 
smokers 
(n=2201)
(Continued from previous page)
Smoking history
Age of smoking initiation 
(years)
·· 31·0 (11·6) 22·7 (8·4) 22·7 (9·1)
Duration of smoking 
(years)
·· 15·7 (10·6) 29·2 (10·1) 28·7 (11·0)
Tobacco sticks smoked 
per day
·· 6·1 (5·0) 18·2 (13·6) 21·0 (11·7)
Tobacco stick-years¶ ·· 83·0 (61·4) 494·3 (378·6) 575·4 (393·3)
Pack-years|| ·· 4·2 (3·1) 24·7 (18·9) 28·8 (19·7)
Current smokers** ·· 2934 (88%) 807 (84%) 1995 (91%)
Former smokers ·· 364 (11%) 145 (15%) 192 (9%)
Missing data ·· 23 (1%) 7 (1%) 14 (1%)
Data are n (%) or mean (SD). Non-smokers self-reported no bidi or cigarette use at baseline survey; light smokers 
reported smoking ten or fewer pack-years of either bidis, cigarettes, or both; and heavy smokers (>10 pack-years) are 
divided into those who smoked cigarettes only and those who smoked bidis with or without cigarettes. ··=not 
applicable. *Smokeless tobacco use was deﬁ ned as self-reported duration of use more than 0 days or quantity more 
than none per day of smokeless tobacco (chewed tobacco, snuﬀ , or rolled tobacco leaves). †Asset index is the non-
monetary aspect of wealth based on the number and type of household items owned (a high positive value indicates 
greater wealth). ‡Lower-income families spend a greater percentage of total income on food. §Manual labour includes 
workers in agricultural, ﬁ shery, and craft industries, plant/machine operators, assemblers, and elementary workers; 
missing data mainly due to retirement. ¶Tobacco stick-years=number of tobacco sticks smoked per day × duration of 
smoking (years). ||Pack-years=tobacco stick-years/20. **Current smokers were deﬁ ned as individuals who reported use 
of at least one tobacco stick per day within 12 months. 
Table 1: Baseline characteristics
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of socioeconomic status alone or in combination; and 
excluded former smokers and smokers of both bidis and 
cigarettes (appendix p 23–24). Results of sensitivity 
analyses showed the conclusions remained unchanged. 
Discussion
In this prospective community-based cohort study of 
unselected men in south Asia, we recorded a high 
prevalence of bidi and cigarette use. Bidi smokers were 
more likely to be from rural areas and have low 
socioeconomic status. Accounting for these diﬀ erences 
and additional baseline risk factors, bidi use was 
consistently associated with signiﬁ cantly increased 
prevalences and relative risks of baseline cardiorespiratory 
symptoms, low ventilatory capacity, and follow-up 
mortality and cardiorespiratory outcomes. Light smokers 
and heavy cigarette smokers also showed increased risks 
of death and cardiovascular events relative to non-
smokers, but not for respiratory events. The observed 
pattern of greater baseline respiratory morbidity and 
higher risks of mortality and cardiorespiratory outcomes 
in heavy bidi smokers suggest that bidis are at least as 
harmful as cigarettes and contribute to the burden of 
tobacco-related disease and deaths in south Asia.
Our reported rates and pattern of bidi use are 
consistent with previous data, indicating a high 
prevalence of bidi smoking in south Asia, with 
geographical19 and socioeconomic variation.20,21 These 
baseline diﬀ erences could potentially confound the 
relation between bidi smoking and health outcomes. 
Our large sample size and data on socioeconomic status 
and other characteristics made it possible to adjust for a 
large number of potentially important confounders, in 
order to derive an unbiased estimate of the independent 
eﬀ ect of bidi smoking on cardiorespiratory health and 
mortality. In addition to the covariates included in the 
ﬁ nal model, we also explored other potential confounders 
in several sensitivity analyses and found their eﬀ ects 
were small and did not substantially change the overall 
model or conclusions.
Non-smokers (n=8438) Light smokers (n=3321) Heavy cigarette smokers (n=959) Heavy bidi smokers (n=2201)
Wheeze
Number 425 234 69 242
Adjusted prevalence (95% CI) 4·3% (3·4–5·4) 5·1% (3·9–6·6) 6·1% (4·2–8·7) 8·0% (6·2–10·2)
Adjusted OR (95% CI) 1·0 1·20 (0·97–1·50) 1·45 (1·10–1·92) 1·95 (1·59–2·39)
p value ·· 0·092 0·009 <0·0001
Cough or sputum
Number 1094 686 214 696
Adjusted prevalence (95% CI) 12·9% (11·0–15·2) 17·9% (15·2–20·8) 21·4% (18·1–25·1) 26·7% (23·2–30·5)
Adjusted OR (95% CI) 1·0 1·46 (1·27–1·69) 1·83 (1·49–2·24) 2·45 (2·07–2·89)
p value ·· 0·0001 0·0001 0·0001
Dyspnoea with usual activity
Number 966 469 170 508
Adjusted prevalence (95% CI) 12·8% (11·4–14·3) 15·0% (13·3–16·8) 19·7% (16·4–23·4) 19·6% (16·6–23·0)
Adjusted OR (95% CI) 1·0 1·20 (1·05–1·39) 1·67 (1·36–2·06) 1·67 (1·36–2·04)
p value ·· 0·010 <0·0001 <0·0001
Chest pain
Number 1241 677 181 612
Adjusted prevalence (95% CI) 15·9% (14·5–17·5) 19·9% (17·9–22·1) 20·2% (17·5–23·1) 23·6% (20·9–26·5)
Adjusted OR (95% CI) 1·0 1·31 (1·16–1·48) 1·33 (1·09–1·63) 1·63 (1·40–1·89)
p value ·· 0·0001 0·006 0·0001
Self-reported baseline symptoms deﬁ ned as those occurring at least weekly in the 6 months before the baseline survey. ORs (relative to non-smokers) were estimated with 
multilevel marginal logistic regression with age, asset index, body-mass index, and centre as covariates. Community was treated as a random eﬀ ect to account for data 
clustering. OR=odds ratio.
Table 2: Self-reported cardiorespiratory symptoms at baseline
Figure 2: Self-reported cardiorespiratory symptoms at baseline
Self-reported baseline symptoms deﬁ ned as those occurring at least weekly in the 6 months before the baseline 
survey. p value for association examined the order eﬀ ect in eﬀ ect size by diﬀ erent smoking groups (as categorical 
variable). Error bars represent 95% CI. 
Wheeze
p<0·0001 for association p<0·0001 for association p<0·0001 for association p<0·0001 for association
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Few contemporary data exist about the respiratory 
eﬀ ects of bidis. Early studies showed an association 
between bidi smoking with chronic cough and sputum.22–25 
In keeping with these ﬁ ndings, we noted that the 
prevalence and risk of cardiorespiratory symptoms were 
consistently higher in heavy bidi smokers than in men in 
the other smoking categories; bidi smokers also had the 
lowest adjusted ventilatory capacity. The ﬁ nding for 
ventilatory capacity had not been consistently documented 
across earlier studies, which were limited by small sample 
sizes and variability in their adjustments of potential 
confounders.24,26,27 Our study is the largest study so far to 
compare spirometry data between bidi and cigarette 
smokers. Our ﬁ ndings suggest lower ventilatory capacity 
and greater airﬂ ow obstruction in heavy bidi smokers, and 
together with a higher prevalence of cardiorespiratory 
symptoms indicate substantially higher rates of obstructive 
respiratory impairment in bidi smokers compared with 
other smokers. Heavy cigarette smokers and light smokers 
also showed lower adjusted lung function than did non-
smokers, but the magnitude of this diﬀ erence did not 
reach signiﬁ cance. This ﬁ nding might relate to the smaller 
sample size in these subgroups or the greater variability in 
the eﬀ ect of cigarette smoking on lung function.
Large population-based studies have examined the 
incidence of cancer, cardiovascular disease, and all-cause 
mortality in tobacco users in south Asia.9,10,28–31 To our 
knowledge, only one other publication has reported on 
the eﬀ ect of bidis separately from cigarettes on all-cause 
mortality (HR relative to never-smokers 1·64 [95% CI 
1·47–1·81] for bidi smokers vs 1·37 [1·23–1·53] for 
cigarette smokers).9 Our work supports and extends this 
ﬁ nding by showing that the risks of cardiorespiratory 
events are also signiﬁ cantly increased with bidi smoking 
independent of socioeconomic status.
Several aspects of this study are worthy of discussion. 
First, our study population included a large number of 
light smokers, particularly of cigarettes. Separating out 
the light smokers provided a more balanced and matched 
distribution of smoking intensity and smoking pattern 
between heavy bidi smokers and heavy cigarette smokers 
for comparison. We found that low-intensity smoking 
can also be associated with respiratory impairment at an 
Non-smokers (n=6701) Light smokers (n=2849) Heavy cigarette smokers 
(n=800)
Heavy bidi smokers 
(n=1691)
FEV1
Change per year, mL/s (95% CI) –22·1 (–23·8 to –20·4) –22·5 (–24·2 to –20·8) –22·7 (–24·7 to –20·8) –23·8 (–25·6 to –22·0)
Diﬀ erence from non-smokers 0 –0·3 (–0·9 to 0·2) –0·6 (–1·5 to 0·3) –1·7 (–2·3 to –1·0)
p value ·· 0·198 0·191 <0·0001
FEV1/FVC ratio
Change per year (95% CI) –0·145% (–0·171 to –0·119) –0·160% (–0·184 to –0·136) –0·158% (–0·184 to –0·132) –0·180% (–0·207 to –0·153)
Diﬀ erence from non-smokers 0 –0·015% (–0·027 to –0·003) –0·013% (–0·028 to 0·002) –0·035% (–0·049 to –0·022)
p value ·· 0·012 0·097 <0·0001
Multilevel marginal linear regression was used to estimate the cross-sectional age-related change in forced expiratory volume in 1 s (FEV1) or FEV1/forced vital capacity (FVC) 
ratio by smoking category adjusted for height, weight, centre, and education (FEV1) or age, height, and centre (FEV1/FVC ratio). Community was treated as a random eﬀ ect. 
Diﬀ erences in the cross-sectional age-related change relative to non-smokers were also adjusted for the same covariates.
Table 3: Cross-sectional age-related changes in FEV1 and FEV1/FVC ratio
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Figure 3: Mean adjusted FEV1 and FEV1/FVC ratio by age group
Multilevel marginal linear regression was used to model forced expiratory volume 
in 1 s (FEV1) by age group and smoking category with height, weight, centre, and 
education as covariates (reference: non-smokers) and community as a random 
eﬀ ect. A similar model was used for the comparison of FEV1/forced vital capacity 
(FVC) ratio by age group and smoking category with age, height, and centre as 
covariates (reference: non-smokers) and community as a random eﬀ ect.
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exposure level that is often considered to be clinically 
trivial. Furthermore, this level of exposure was associated 
with increased risks of cardiovascular events and 
mortality compared with not smoking. This ﬁ nding 
suggests that there is no threshold that can be considered 
safe from the harmful eﬀ ects of tobacco smoking. 
Second, bidis are smaller with less tobacco content and 
are generally sold in diﬀ erent quantities from cigarettes. 
These diﬀ erences make comparison of the two tobacco 
types using a common unit of exposure such as pack-
years diﬃ  cult. To maintain consistency and allow ease of 
comparison with the literature on tobacco, we continued 
to use pack-years to deﬁ ne the groups. However, any 
interpretation of the eﬀ ect size of bidi use on outcomes 
must take into account of the lower tobacco content in 
bidis compared with cigarettes.7 Finally, only participants 
with no previous cardiorespiratory morbidity, cancer, or 
HIV infection were analysed for follow-up events to avoid 
the eﬀ ect of reverse causality on our ﬁ ndings.
There are limitations and strengths to our study. It was 
not feasible to aim for strict proportionate sampling in this 
large prospective cohort study. The design did not use 
standard random sampling but adopted a design that 
avoided biases in levels of risk factors and prevalence of 
disease conditions. Second, lung function was measured 
with a portable spirometer that did not provide ﬂ ow-volume 
curves and therefore veriﬁ cation of individual eﬀ ort was 
not possible. However, we had previously validated this 
method by comparing data obtained in certiﬁ ed pulmonary 
function laboratories with data obtained by PURE methods 
for 531 participants from participating sites including south 
Asia; we noted high correlations without biases.16 Further, 
there is no a-priori reason to expect diﬀ erential eﬀ ects in 
methods on spirometry measurements between diﬀ erent 
smoking groups. The major strengths of our study include 
the large sample size, the prospective and standardised 
approach to data collection and outcome ascertainment, all 
of which provide for a robust and systematic analysis, and 
adjustment for a large number of potential confounders.
Our ﬁ ndings have important public health implications. 
South Asia is the second largest consumer of tobacco in 
the world, with more than 130 million tobacco smokers.2 
More than half these smokers use bidis, particularly 
among the poorest and most vulnerable sectors of the 
population. Therefore the health impact of bidis is highly 
relevant in this region. Furthermore, as the current trend 
of bidi exportation continues, the global impact of bidis 
will rise, particularly among young adults. Our ﬁ ndings 
suggest that bidis are at least as harmful as cigarettes on 
cardiorespiratory health and mortality, despite having 
substantially less tobacco content than cigarettes. Control 
of bidis should be an integral part of any anti-tobacco 
framework, both regionally and globally, with the greatest 
potential eﬀ ects to be seen in poor and young people.
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Non-smokers 
(n=7554)
Light smokers 
(n=2966)
Heavy cigarette 
smokers 
(n=819)
Heavy bidi 
smokers 
(n=1925)
Cardiovascular events
Number 234 144 65 109
Adjusted incidence (95% CI) 3·1%
(2·4–3·9)
4·6%
(3·4–6·3)
4·4%
(3·0–6·3)
5·1%
(3·5–7·3)
Adjusted HR (95% CI) 1·0 1·45
(1·13–1·84)
1·47
(1·05–2·06)
1·55
(1·17–2·06)
p value ·· 0·003 0·023 0·002
Respiratory events
Number 99 61 27 82
Adjusted incidence (95% CI) 0·7%
(0·4–1·1)
0·9%
(0·6–1·5)
0·8%
(0·4–1·5)
1·3%
(0·8–2·2)
Adjusted HR (95% CI) 1·0 1·30 
(0·91–1·85)
1·21
(0·70–2·07)
1·73
(1·23–2·45)
p value ·· 0·154 0·496 0·002
Deaths
Number 279 165 58 183
Adjusted incidence (95% CI) 2·3%
(1·7–3·0)
3·1%
(2·1–4·5)
3·3%
(2·2–5·0)
3·8%
(2·7–5·5)
Adjusted HR (95% CI) 1·0 1·28 
(1·02–1·62)
1·59
(1·13–2·24)
1·56
(1·22–1·98)
p value ·· 0·034 0·008 <0·0003
New cardiovascular events (cardiovascular-related death, myocardial infarction, heart failure, stroke, and 
cardiovascular-related hospital admission), respiratory events (chronic obstructive pulmonary disease [COPD], 
pneumonia, tuberculosis, asthma), and all-cause mortality at a mean follow-up of 5·6 years. Incidence and HRs 
(relative to non-smokers) for all-cause mortality and cardiovascular events were adjusted for age, body-mass index, 
asset index, education, handgrip, INTERHEART risk score, diabetes, and hypertension, and centre as ﬁ xed-eﬀ ect 
covariates, and community as a random eﬀ ect in a multilevel marginal Cox proportional hazards model. For respiratory 
events, the same model was used but without INTERHEART risk score, diabetes, and hypertension as covariates in the 
model. HR=hazard ratio. *Participants with missing data or with self-reported diagnoses of stroke, heart disease, 
cancer, COPD, asthma, tuberculosis, or HIV infection were excluded from the analysis.  
Table 4: Respiratory events, cardiovascular events, and deaths during follow-up*
Figure 4: Respiratory events, cardiovascular events, and deaths during follow-up
New cardiovascular events (cardiovascular-related death, myocardial infarction, heart failure, stroke, and 
cardiovascular-related hospital admission), respiratory events (chronic obstructive pulmonary disease, pneumonia, 
tuberculosis, asthma), and all-cause mortality at a mean follow-up of 5·6 years. Hazard ratios (relative to 
non-smokers) for all-cause mortality and cardiovascular events were estimated with a marginal Cox proportional 
hazards model with age, education, asset index, body-mass index, handgrip, self-reported diabetes, hypertension, 
INTERHEART risk score, and centre as ﬁ xed eﬀ ects and community as a random eﬀ ect. For respiratory events, the 
same model was used but without INTERHEART risk score, diabetes, and hypertension as covariates in the model. 
p value for association examined the order eﬀ ect in eﬀ ect size by diﬀ erent smoking groups (as categorical 
variable). Error bars represent 95% CI.
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